CN115154487A

CN115154487A - Polysaccharide salt spray mixture containing probiotic fermentation liquor for protecting respiratory tract and application thereof

Info

Publication number: CN115154487A
Application number: CN202211015334.7A
Authority: CN
Inventors: 王静; 王晓娟
Original assignee: Individual
Current assignee: Jiangxi Salt Selection Technology Co ltd
Priority date: 2022-08-24
Filing date: 2022-08-24
Publication date: 2022-10-11
Anticipated expiration: 2042-08-24
Also published as: CN115154487B

Abstract

The invention discloses a polysaccharide salt spray mixture containing probiotic fermentation liquor and used for protecting respiratory tracts and application thereof. The main components of the polysaccharide in the invention are methyl hesperidin, modified lentinan and linalool oxide. The methyl modified hesperidin is found to be more beneficial to the absorption of a human body, and has better protective effect on respiratory tract. The modified lentinan has better anti-tumor and antibacterial effects. The probiotic fermentation liquor, methyl hesperidin, sulphated modified lentinan and linalool oxide have a certain synergistic effect, so that the antiviral, antiviral and respiratory tract protecting effects are more effective and lasting.

Description

Polysaccharide salt spray mixture containing probiotic fermentation liquor for protecting respiratory tract and application thereof

Technical Field

The invention belongs to the technical field of biology, and relates to a polysaccharide mixture for protecting a respiratory tract, in particular to a polysaccharide mixture for protecting the respiratory tract and a salt spray mixture thereof.

Background

In recent years, the prevalence rate of lung diseases such as chronic obstructive pulmonary disease and asthma caused by bad living habits, environmental pollution and the like is high; the large-scale outbreaks of respiratory infectious diseases such as human avian influenza and influenza a also present new challenges for the prevention and treatment of respiratory diseases. The mucosal immune system, which is the first defense line of the body defense, plays an important role in resisting invasion of pathogenic microorganisms, so that the research on the mucosal immunity of the respiratory tract is becoming one of the hot spots in clinical and scientific research. The research on the relationship between TCM and it is increasing, and researchers have studied the relationship between TCM and mucosal immunity of respiratory tract by means of "lung curves in nose" and "lung and large intestine are exterior and interior".

The aerosol inhalation therapy is a common means for treating respiratory system diseases, and as the name suggests, the salt spray physiotherapy is a technology for obtaining treatment effect by inhalation of a physiotherapist after salt brine is atomized by special equipment, and the treatment effect is relatively ideal. The basic principle of aerosol inhalation therapy is: the medical atomizer depolymerizes and atomizes the medicinal powder into medicinal powder aerosol, and the medicinal powder aerosol is inhaled by a patient to reach a focus position. Compared with the administration modes such as oral administration, injection and the like, the aerosol inhalation therapy has the advantages of quick drug effect, small toxic and side effect and wide applicable population.

Methyl hesperidin is a natural flavonoid compound derived from fruits and vegetables, but the content of the methyl hesperidin in plant species is very small, and most of the methyl hesperidin is modified. The existing literature proves that methyl hesperidin has excellent antibacterial, antiviral and antifungal effects, but the existing literature does not prove the effect on respiratory tract infection. The lentinan has the effects of improving immunity, resisting tumors and the like, the biological activity of the lentinan and the derivative thereof has a close relation with the molecular structure of the lentinan, and the sulfated lentinan has high water solubility and also has an obvious anti-tumor effect.

A large number of experiments prove that the methyl hesperidin can be matched with the modified lentinan to have an obvious effect of resisting respiratory tract infection. The invention combines the advantages of easy absorption of sulfated lentinan, methyl hesperidin and linalool oxide to prepare the salt mist moderator. The salt spray mixture can not only affect secretion of bronchial tube, but also reduce formation of coagulated secretion in tube, regulate pulmonary alveolus surfactant, and improve pulmonary alveolus surface tension. The probiotic fermentation liquor has certain antibacterial and bactericidal capacity. The salt particles can dehydrate the protein structure of bacteria, and has the effects of sterilizing, resisting inflammation, dissolving sputum, improving the ventilation condition of trachea, etc.

The invention aims to provide a mixture of salt spray and probiotic fermentation supernatant for protecting respiratory tract, which has the effect of resisting virus and protecting the respiratory tract.

Disclosure of Invention

In order to achieve the purpose, the invention adopts the following technical scheme:

a polysaccharide mixture for protecting respiratory tract and its salt spray mixture are disclosed, which is characterized by the following: according to the mass percentage, the biological feed comprises 4-5% of methyl hesperidin, 5-10% of modified lentinan, 0.5-2% of linalool oxide, 10-20% of salt solution and 20-30% of probiotic fermentation supernatant.

Preferably, the modified lentinan is sulfated lentinan.

The salt according to the invention may be pure sodium chloride or a sea salt containing other minerals.

The probiotic used in the present invention is streptococcus thermophilus, which is considered as a "Generally Recognized As Safe (GRAS)" ingredient and is widely used in the production of some important fermented dairy products, including yoghurts and cheeses. Streptococcus thermophilus also has functional activities such as production of exopolysaccharides, bacteriocins and vitamins. In addition, the streptococcus thermophilus can also be used as a potential beneficial bacterium, and experiments prove that the streptococcus thermophilus has transport activity and certain gastrointestinal tract adhesion.

The group of the invention discovers that the streptococcus thermophilus fermentation liquid can generate synergistic effect with methyl hesperidin, modified lentinan and linalool oxide, so that the streptococcus thermophilus fermentation liquid has certain respiratory tract protection, antiviral and antibacterial effects. Presumably, the reason is that sulfated lentinan has the function of improving immunity, and methyl hesperidin can maintain normal permeability of blood vessels, so that the immunity of the modified lentinan is enhanced. In addition, the fermentation liquor of the streptococcus thermophilus contains a large amount of substances such as vitamins and the like, and the methyl hesperidin can enhance the capacity of the vitamins, so that the effect of enhancing the immunity can be achieved. The experiment also carries out experiments on lentinan, methyl hesperidin and probiotic fermentation liquor, and finds that the unmodified lentinan has poor water solubility and is difficult to be matched with the probiotic fermentation liquor and the methyl hesperidin to play a better role.

The group of the invention prepares the mixture of the probiotics, methyl hesperidin and sulfated lentinan into salt mist, mixed solution and the like, and finds that the salt mist mixture can better act on the respiratory tract and better protect the respiratory tract.

The salt fog mixture prepared by the invention can be atomized by special atomization equipment for human physical therapy, and can also be concentrated and soaked in porous media such as sponge to prepare a chip which is placed in a mask for physical therapy.

The preparation method of the polysaccharide and the salt spray mixture thereof comprises the following steps:

s1, weighing 30-50g of hesperidin, adding into a three-neck flask, adding 200-400mL of water, starting stirring, stirring to form a suspension, adding 10-20g of calcium hydroxide, slowly dropwise adding 10-15mL of dimethyl carbonate, reacting at 30-60 ℃ for 6 hours, extracting with n-butyl alcohol for 2 times, combining organic phases, washing with water for 1 time, washing with saturated salt water for 1 time, recovering n-butyl alcohol under reduced pressure to obtain a methyl hesperidin crude product, adding 240mL of 95% ethanol into the crude product, heating to 60 ℃ for dissolution, filtering while hot, cooling filtrate at room temperature for crystallization for 2 days, performing suction filtration, and drying at 80 ℃ to obtain orange yellow crystalline powder, namely methyl hesperidin.

S2, placing 10mL of anhydrous pyridine into a 500mL round-bottom flask, cooling to 0 ℃ in an ice-water bath, slowly adding 20mL of chlorosulfonic acid under magnetic stirring, continuously stirring at room temperature for 30min, sealing, and refrigerating in a refrigerator.

S3, dissolving a certain amount of lentinan in 40mLN N-dimethylformamide, stirring at room temperature for 30-60min, adding an esterification reagent, and stirring in a water bath at 60 ℃ for 2-3h. After the reaction is finished, adding pre-cooled redistilled water to dilute the solution, adding sodium hydroxide to neutralize the solution, centrifuging, dialyzing with running water for 3 days, dialyzing with distilled water for 1 day, carrying out rotary evaporation and concentration, adding absolute ethyl alcohol, carrying out alcohol precipitation at the temperature of 4 ℃ for 24 hours, centrifuging, and carrying out freeze drying to obtain white sulfated lentinan.

S4, placing linalool and formic acid in a water bath, controlling the reaction temperature of the water bath to be 60-65 ℃, then dropwise adding 30% aqueous hydrogen peroxide, finishing dropping for 30min, controlling the temperature of the dropwise adding process to be 65-70 ℃, keeping the temperature and stirring for 2h after the dropwise adding is finished, cooling, then adding saturated aqueous sodium chloride, extracting with benzene, combining extract liquor, washing the extract liquor with 10% aqueous sodium carbonate solution and water to be neutral, and drying with anhydrous sodium sulfate; after drying, the benzene residue is removed by evaporation, then the distillation is carried out under reduced pressure, and the fraction with the boiling range of 70-74 ℃ is collected under 799.8 Pa; 75-79 ℃ (II); 80 to 84 ℃ (III); 85-102 ℃ (IV); taking the fraction (II), namely the linalool oxide prepared by the invention.

S5, inoculating an environment-friendly preserved streptococcus thermophilus on a TPY culture medium, carrying out anaerobic culture at 40 ℃ for 24 hours, selecting a single colony growing well, inoculating the single colony into the TPY culture medium, activating, and repeating twice.

S6, inoculating the activated strain into a culture medium according to the volume ratio of 4%, standing and culturing for 8h in an anaerobic incubator at 40 ℃, filtering, centrifuging for 20min at 3000r/min, and taking supernatant for ultraviolet sterilization to obtain the probiotic fermentation liquor.

S7, adding the prepared mixture of methyl hesperidin and modified lentinan into probiotic fermentation liquor according to a certain mass ratio, and then adding a salt solution to fully mix the mixture to obtain the prepared salt spray mixture.

S8, atomizing the prepared salt spray mixture through professional atomizing equipment, or concentrating the salt spray mixture, soaking the mask filter element with the concentrated salt spray mixture, and placing the mask filter element into a mask for physiotherapy.

Compared with the prior art, the invention has the beneficial effects that:

1. the salt spray, the probiotic fermentation liquor, the methyl hesperidin and the modified lentinan have a certain synergistic effect, so that the effect of protecting the respiratory tract is more obvious. The streptococcus thermophilus fermentation liquid can generate synergistic effect with methyl hesperidin and modified lentinan, so that the streptococcus thermophilus fermentation liquid has certain respiratory tract protection, antiviral and antibacterial effects. Presumably, the reason is that sulfated lentinan has the function of improving immunity, and methyl hesperidin can maintain normal permeability of blood vessels, so that the immunity of the modified lentinan is enhanced. In addition, the fermentation liquor of the streptococcus thermophilus contains a large amount of substances such as vitamins and the like, and the methyl hesperidin can enhance the capacity of the vitamins, so that the effect of enhancing the immunity can be achieved.

2. The salt spray mixture prepared by the invention has good water solubility and is easier to absorb.

3. The salt spray mixture prepared by the invention is not applicable to toxic and harmful components in the preparation process, and is safer.

4. Because the fermentation liquor of the streptococcus thermophilus contains a large amount of vitamin substances, the linalool oxide can generate synergistic action with components such as vitamin E and the like, so that the antioxidant effect of the streptococcus thermophilus is enhanced.

Drawings

FIG. 1 is a graph showing cell viability in examples 1 to 4, comparative examples 1 to 6 and a negative control group prepared according to the present invention.

FIG. 2 shows the secretion amounts of TNF-alpha proinflammatory factor in examples 1-4, comparative examples 1-6, blank control, and lipopolysaccharide control groups prepared according to the present invention

FIG. 3 shows the secretion amounts of IL-6 proinflammatory factors in examples 1-4 and comparative examples 1-6 prepared according to the present invention, in comparison with a blank control and a lipopolysaccharide control group.

FIG. 4 shows the secretion amounts of IL-1. Beta. Proinflammatory factor in examples 1 to 4 and comparative examples 1 to 6 prepared according to the present invention, in comparison with a blank control and a lipopolysaccharide control group.

Fig. 5 is a molecular structural formula of methyl hesperidin prepared in example 3 of the present invention.

FIG. 6 is an infrared spectrum of the modified lentinan prepared in example 4 of the present invention.

FIG. 7 shows linalool oxide prepared according to the present invention.

FIG. 8 is the hydrogen spectrum of linalool oxide prepared according to the present invention.

FIG. 9 is a carbon spectrum of linalool oxide prepared according to the present invention.

Detailed Description

In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is described in further detail below with reference to specific embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and do not limit the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Example 1

S1, weighing 30g of hesperidin, adding the hesperidin into a three-neck flask, adding 200mL of water, starting stirring, stirring to form a suspension, then adding 10g of calcium hydroxide, slowly dropwise adding 10mL of dimethyl carbonate, reacting at 30 ℃ for 6 hours, extracting with n-butyl alcohol for 2 times, combining organic phases, washing with water for 1 time, washing with saturated salt for 1 time, recovering n-butyl alcohol under reduced pressure to obtain a methyl hesperidin crude product, adding 240mL of ethanol with the mass fraction of 95% into the crude product, heating to 60 ℃ for dissolution, filtering while hot, cooling and crystallizing filtrate at room temperature for 2 days, performing suction filtration, and drying at 80 ℃ to obtain orange yellow crystalline powder, namely methyl hesperidin.

S3, dissolving a certain amount of lentinan in 40mL of N, N-dimethylformamide, stirring at room temperature for 30min, adding an esterification reagent, and stirring in a water bath at 60 ℃ for 2h. After the reaction is finished, adding precooled redistilled water to dilute the solution, adding sodium hydroxide to neutralize the solution, centrifuging, dialyzing with running water for 3 days, dialyzing with distilled water for 1 day, carrying out rotary evaporation and concentration, adding absolute ethyl alcohol, carrying out alcohol precipitation at the temperature of 4 ℃ for 24 hours, centrifuging, and carrying out freeze drying to obtain white sulfated lentinan.

S4, placing linalool and formic acid in a water bath, controlling the reaction temperature of the water bath to be 60 ℃, then dropwise adding 30% aqueous hydrogen peroxide solution, finishing dropping for 30min, controlling the temperature in the dropwise adding process to be 65 ℃, keeping the temperature and stirring for 2h after the dropwise adding is finished, cooling, then adding saturated aqueous sodium chloride solution, extracting with benzene, combining extract liquor, washing the extract liquor with 10% aqueous sodium carbonate solution and water to be neutral, and drying with anhydrous sodium sulfate; after drying, the benzene residue is removed by evaporation, then the distillation is carried out under reduced pressure, and the fraction with the boiling range of 70-74 ℃ is collected under 799.8 Pa; 75-79 ℃ (II); 80 to 84 ℃ (III); 85-102 ℃ (IV); taking a fraction (II), namely linalool oxide prepared by the invention.

S5, inoculating an environmentally-friendly preserved streptococcus thermophilus on a TPY culture medium, carrying out anaerobic culture at 40 ℃ for 24 hours, selecting a single colony growing well, inoculating the single colony into the TPY culture medium, activating, and repeating twice.

S7, mixing the prepared methyl hesperidin, the modified lentinan, the linalool oxide, the salt solution, the probiotic fermentation supernatant and water in a mass ratio of: 4%, 5%, 0.6%, 10%, 20%, 60.4% to obtain the salt spray mixture.

Example 2

The procedure of example 2 was substantially the same as that of example 1, except that the salt spray mixture in step S7 was prepared in the following mass ratio: mixing 5% of methyl hesperidin, 10% of modified lentinan, 1.0% of linalool oxide, 20% of salt solution, 30% of probiotic fermentation supernatant and 34% of water.

Example 3

The procedure in example 3 was substantially the same as in example 1, except that the salt spray mixture in step S7 was prepared in the following mass ratio: mixing 4% of methyl hesperidin, 10% of modified lentinan, 1.0% of linalool oxide, 20% of salt solution, 20% of probiotic fermentation supernatant and 45% of water.

Example 4

The procedure of example 4 was substantially the same as that of example 1 except that the salt spray mixture in step S7 was prepared in the following mass ratio: 5% of methyl hesperidin, 8% of modified lentinan, 0.6% of linalool oxide, 15% of salt solution, 13% of probiotic fermentation supernatant and 58.4% of water.

Comparative example 1

Comparative example 1 was prepared by the same procedure as in example 1 except that no sea salt and no probiotic fermentation broth were added in step S7.

Comparative example 2

Comparative example 2 is substantially the same as the preparation procedure of example 1, except that no methyl hesperidin and no probiotic fermentation broth were added in step S7.

Comparative example 3

Comparative example 3 is substantially the same as the preparation procedure of example 1, except that no methyl hesperidin and no sea salt were added in step S7.

Comparative example 4

Comparative example 4 is substantially the same as the preparation procedure of example 1, except that no sea salt is added in step S7.

Comparative example 5

Comparative example 5 is essentially the same as the preparation procedure of example 1, except that no methyl hesperidin is added in step S7.

Comparative example 6

Comparative example 6 is substantially the same as the preparation procedure of example 1, except that no probiotic fermentation broth was added in step S7.

1. Cytotoxicity assays

Observing the growth state of cells, scraping the cells when the cells are logarithmically grown, centrifuging, counting the cells, and adjusting the concentration so that the final concentration of the cells is 4X 10 ⁵ Cells/ml and spotted into 96 well plates at a volume of 100. Mu.l per well, for overnight incubation. The sample prepared in the experiment is dissolved by a proper amount of dimethyl sulfoxide with the concentration less than or equal to 0.1 percent, DMEM is used for preparing sample stock solution with the concentration of 20 mu g/ml, a negative control group and a sample group are arranged, and each group is provided with 3 parallel holes. After overnight incubation, 50. Mu.l (5 mg/mL) of MTT was added, after 4 hours the supernatant was discarded, and DMSO was added to the wells at 150. Mu.l per well and the absorbance at 570nm was measured for each well without statistical difference between groups.

As can be seen from FIG. 1, both the examples prepared according to the present invention and the comparative examples are non-toxic to cells. As can be seen from the data, the cell survival rate of the examples is higher than that of the comparative examples, which is closely related to methyl hesperidin, modified lentinan and the like.

2. Effect of samples on inducing secretion of IL-1 beta, TNF-alpha and IL-6 cytokines

Observing the growth state of the cells until the cells grow to a concentration of about 4X 10 cells per ml ⁵ For each cell, the cells were spotted onto 24-well plates at 500. Mu.l per well and cultured overnight. The experiment is divided into a blank control group, a lipopolysaccharide group and a sample group. The sample group was supplemented with the stock solution of the sample prepared in the present invention to 250. Mu.L with DMEM so that the final concentration was 2. Mu.g/ml. The other groups were loaded with an equal amount of DMEM, while each experimental group was plated in three parallel wells. One hour after the administration, DMEM was added to the blank group, 250. Mu.l of lipopolysaccharide at 1. Mu.g/ml was added to the lipopolysaccharide group and the sample group, and after 12 hours of culture, the supernatant was divided and stored at-80 ℃ to allow measurement of each cytokine without statistical difference between the groups.

The reaction plate was removed from the sealed bag, a 20-fold dilution of primary antibody was added to the corresponding well with the coating solution at 100. Mu.l per well, and the plate was sealed with a sealing plate membrane overnight at 4 ℃. The liquid in the plate was spun off and the plate was washed four times with wash solution. Add 200. Mu.L of sample dilution, seal plate, and shake at room temperature for 1 hour. The liquid in the plate was spun off and the plate was washed four times with wash solution. Respectively adding 100 mul of diluted IL-1 beta, TNF-alpha and IL-6 standard substances and a sample to be detected, and shaking for two hours at room temperature. The liquid in the plate was spun off and the plate was washed four times with wash solution. Add 200-fold dilutions of secondary IL-1. Beta., TNF-. Alpha., IL-6, 100. Mu.l per well, and shake for one hour at room temperature. The liquid in the plate was spun off and the plate was washed four times with wash solution. Adding 100 μ l of horse radish peroxidase, shaking at room temperature for 30min, removing liquid in the plate, and washing the plate with washing solution five times. Adding 100ml of 3,3', 5' -tetramethylbenzidine substrate color development solution into each well, and developing for 15 minutes in a dark place. 100 μ L of stop solution was added. The OD (450 nm) of each reaction well was measured by a microplate reader. And (5) making a standard curve according to the standard substance of each concentration and the corresponding OD value. And calculating the concentration of the corresponding cell factor in each sample to be detected according to the standard curve.

The test results are shown in the following table:

TABLE 1

TABLE 2

Lipopolysaccharide can enter into body to trigger expression of related protein gene in inflammation signal transduction pathway of body. TNF-alpha, IL-6, IL-1 beta are pro-inflammatory factors which in turn induce the secretion of a number of inflammatory mediators, such as prostaglandins, nitric oxide, leukotrienes, etc., triggering the "cascade effect".

FIG. 1 is a graph showing the cell viability of the negative control group and the sample group. It can be seen from the figure that there is no significant difference in the survival rate between the example group prepared by the present invention and the blank negative control group, and therefore it can be seen that the sample prepared by the present invention is non-toxic and harmless to the cells. In addition, the samples prepared by the method also have certain promotion effect on the growth of the cells.

FIG. 2, FIG. 3 and FIG. 4 show the secretion amounts of three pro-inflammatory factors TNF- α, IL-6 and IL-1 β in the samples prepared by the present invention, a blank control and a lipopolysaccharide control group, respectively. When lipopolysaccharide enters into body, it can cause release of many active substances such as cytokine and pro-inflammatory factor, such as IL-1 beta, TNF-alpha and IL-6, through recognition and signal transmission. IL-6 is an important and long-lasting cytokine that stimulates effector cells to release inflammatory mediators and the production of acute phase proteins, which play an important role in both the homeostasis of the hematopoietic system, neuroendocrine and bone metabolism, and increased IL-6 secretion in the body under infection, injury and other stress conditions. This dysregulated high concentration of IL-6 triggers a series of inflammatory processes. TNF is involved in thermogenesis and promotes the expression of other inflammatory mediators, playing a key role in inflammatory processes, and TNF-alpha, a product that is also thought to be involved in the induction of other pro-inflammatory mediators and can damage blood vessels at the site of inflammation, causing microvascular hemorrhagic responses. IL-1 beta is highly expressed in acute lung injury animal model and alveolar lavage fluid of patients with respiratory distress syndrome, and IL-1 beta can stimulate effector cells to produce a large amount of cytokines, such as IL-8, monocyte chemotactic protein and macrophage inflammatory protein, so as to cause the aggregation of inflammatory cells such as leucocytes, monocyte macrophages and the like. IL-1 β also causes damage to epithelial cells and has the potential to cause pulmonary fibrosis, and also increases vascular permeability, causes abnormalities in alveolar surfactant, and exacerbates pulmonary edema.

As can be seen from FIGS. 2, 3 and 4, the contents of IL-1. Beta., TNF-. Alpha.and IL-6 in lipopolysaccharide groups reached 18.12ng/ml, 139.52. Mu.g/ml and 12.32. Mu.g/ml, but the contents of IL-1. Beta., TNF-. Alpha.and IL-6 in examples 1 to 4 were greatly reduced, indicating that the anti-inflammatory effect was significant in the examples. The reason may be that methyl hesperidin and the modified lentinan in the embodiment group have synergistic effect, and can inhibit the expression of some protein genes, so as to inhibit the secretion of some proinflammatory factors in cells. In comparative examples 1-6, the contents of IL-1. Beta., TNF-. Alpha., and IL-6 were decreased, but the decrease was small, and it was difficult to achieve the anti-inflammatory and respiratory tract-protecting effects. Meanwhile, the substances in the examples have good synergistic effect by comparing the examples with the comparative examples.

As can be seen from the figure, the samples prepared according to the present invention have a very good anti-inflammatory effect. It is demonstrated that the samples prepared by the present invention can reduce the occurrence of inflammation by inhibiting the secretion of cytokines. In addition, the comparative sample prepared by the invention has weak effect of resisting inflammation, but the sample of the embodiment has good effect of resisting inflammation, which shows that the methyl hesperidin and the modified lentinan interact with the probiotic fermentation liquor and the salt spray, so that the methyl hesperidin and the modified lentinan have good effects of resisting inflammation and protecting respiratory tract.

Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that modifications may be made to the embodiments or portions thereof without departing from the spirit and scope of the invention.

Claims

1. A polysaccharide salt spray mixture for the protection of the respiratory tract comprising a probiotic fermentation broth, characterized in that: according to the mass percentage, the composition comprises 4-5% of methyl hesperidin, 5-10% of modified lentinan, 0.5-2% of linalool oxide, 10-20% of salt solution, 20-30% of probiotic fermented supernatant and the balance of water; the modified lentinan is obtained by carrying out sulfation treatment on lentinan; the probiotic is streptococcus thermophilus.

2. The polysaccharide salt spray mixture for protecting the respiratory tract, which contains probiotic fermentation broth according to claim 1, is characterized in that the preparation method of the methyl hesperidin comprises the following steps: weighing hesperidin, adding into a three-necked flask, adding 200-400mL of water, starting stirring, stirring to form a suspension, then adding calcium hydroxide, slowly dropwise adding dimethyl carbonate, controlling the reaction temperature at 30-60 ℃ for reaction, extracting with n-butyl alcohol for 2 times, combining organic phases, washing with water for 1 time, washing with saturated salt water for 1 time, recovering n-butyl alcohol under reduced pressure to obtain a methyl hesperidin crude product, adding 240mL of ethanol with the mass fraction of 95% into the crude product, heating to dissolve, filtering while hot, cooling the filtrate at room temperature for crystallization for 2 days, carrying out suction filtration, and drying.

3. The polysaccharide salt spray mixture containing probiotic fermentation broth for respiratory tract protection according to claim 1, wherein the sulphation treatment of lentinan is: dissolving lentinan in N, N-dimethylformamide, stirring at room temperature for 30-60min, adding esterification reagent, stirring in water bath for 2-3h, adding pre-cooled redistilled water to dilute the solution after the reaction is finished, adding sodium hydroxide to neutralize the solution, centrifuging, dialyzing with running water, dialyzing with distilled water, rotary evaporating to concentrate, adding anhydrous ethanol, precipitating with ethanol at 4 deg.C, centrifuging, and freeze drying to obtain white sulfated lentinan.

4. The polysaccharide salt spray mixture for protecting the respiratory tract, which contains probiotic fermentation broth, according to claim 1, is prepared by the following method: placing linalool and formic acid in a water bath, controlling the reaction temperature of the water bath to be 60-65 ℃, then dropwise adding aqueous hydrogen peroxide, finishing dropping for 30min, controlling the temperature of the dropwise adding process to be 65-70 ℃, keeping the temperature and stirring after the dropwise adding is finished, cooling, then adding saturated aqueous sodium chloride, extracting with benzene, combining extract liquor, washing the extract liquor with 10% aqueous sodium carbonate solution and water to be neutral, and drying with anhydrous sodium sulfate; after drying, the benzene residue is removed by evaporation, then the distillation is carried out under reduced pressure, and the fraction with the boiling range of 70-74 ℃ is collected under 799.8 Pa; 75-79 ℃ (II); 80 to 84 ℃ (III); 85-102 ℃ (IV); taking a fraction (II), namely linalool oxide prepared by the invention.

5. The polysaccharide salt spray mixture for the protection of the respiratory tract comprising probiotic fermentation broth according to claim 3, wherein: preparation of esterification reagent: placing anhydrous pyridine in 500mL round-bottom flask, cooling in ice-water bath, slowly adding chlorosulfonic acid under magnetic stirring, stirring at room temperature for 30min, sealing, and refrigerating in refrigerator.

6. The polysaccharide salt spray mixture for the protection of the respiratory tract comprising a probiotic fermentation broth according to claim 1, wherein: the preparation method of the fermentation liquor comprises the following steps: s1, inoculating an environmentally-friendly preserved streptococcus thermophilus on a TPY (thermoplastic vulcanizate) culture medium, carrying out anaerobic culture, selecting a single colony growing well, inoculating the single colony to the TPY culture medium, activating, and repeating twice; s2, inoculating the activated strain into a culture medium according to the volume ratio of 4%, standing and culturing in an anaerobic incubator, filtering, centrifuging, and performing ultraviolet sterilization on the supernatant to obtain the probiotic fermentation liquor.

7. The polysaccharide salt spray mixture for the protection of the respiratory tract comprising a probiotic fermentation broth according to any one of claims 1 to 6, characterized in that: the salt is sodium chloride or other mineral sea salt.

8. Polysaccharide salt spray mixture for the protection of the respiratory tract comprising a probiotic fermented liquid according to any of claims 1 to 7, characterized in that: the salt-fog mixture is concentrated and soaked in a porous medium to form a chip, and the chip is placed in a mask for physiotherapy or is subjected to atomization treatment for physiotherapy.

9. A chip for a mask, characterized in that: a polysaccharide salt spray mixture for the protection of the respiratory tract comprising a probiotic fermented liquid according to any of claims 1 to 7.

10. A therapeutic mask comprising the chip of claim 9.